Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pasithea Therapeutics Equity Warrant Exp 11th Aug 2026 KTTAW

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more

Recent & Breaking News (NDAQ:KTTAW)

Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

GlobeNewswire November 24, 2021

Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.

GlobeNewswire November 23, 2021

Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint

GlobeNewswire November 17, 2021

Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy

GlobeNewswire November 11, 2021

Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair

GlobeNewswire November 9, 2021

Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

GlobeNewswire October 27, 2021

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

GlobeNewswire October 14, 2021

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

GlobeNewswire October 11, 2021

Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

GlobeNewswire September 29, 2021

Pasithea Therapeutics Corp. Announces Closing of $24.0 Million Initial Public Offering

GlobeNewswire September 17, 2021